Search Results - "Umeton, R."

Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis by Buscarinu, M. C., Romano, S., Mechelli, R., Pizzolato Umeton, R., Ferraldeschi, M., Fornasiero, A., Reniè, R., Cerasoli, B., Morena, E., Romano, C., Loizzo, N. D., Umeton, R., Salvetti, M., Ristori, G.

“…Changes of intestinal permeability (IP) have been extensively investigated in inflammatory bowel diseases (IBD) and celiac disease (CD), underpinned by a known…”
Get full text

Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer by Lamberti, G., Spurr, L.F., Li, Y., Ricciuti, B., Recondo, G., Umeton, R., Nishino, M., Sholl, L.M., Meyerson, M.L., Cherniack, A.D., Awad, M.M.

“…Programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) is the primary clinically-available biomarker of response to immunotherapy in…”
Get full text

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers by Sabari, J.K., Leonardi, G.C., Shu, C.A., Umeton, R., Montecalvo, J., Ni, A., Chen, R., Dienstag, J., Mrad, C., Bergagnini, I., Lai, W.V., Offin, M., Arbour, K.C., Plodkowski, A.J., Halpenny, D.F., Paik, P.K., Li, B.T., Riely, G.J., Kris, M.G., Rudin, C.M., Sholl, L.M., Nishino, M., Hellmann, M.D., Rekhtman, N., Awad, M.M., Drilon, A.

“…MET exon 14 alterations are actionable oncogenic drivers. Durable responses to MET inhibitors are observed in patients with advanced MET exon 14-altered lung…”
Get full text

A staged screening of registered drugs highlights remyelinating drug candidates for clinical trials by Eleuteri, C., Olla, S., Veroni, C., Umeton, R., Mechelli, R., Romano, S., Buscarinu, MC, Ferrari, F., Calò, G., Ristori, G., Salvetti, M., Agresti, C.

“…There is no treatment for the myelin loss in multiple sclerosis, ultimately resulting in the axonal degeneration that leads to the progressive phase of the…”
Get full text

IFN-β and multiple sclerosis: From etiology to therapy and back by Annibali, V, Mechelli, R, Romano, S, Buscarinu, M.C, Fornasiero, A, Umeton, R, Ricigliano, V.A.G, Orzi, F, Coccia, E.M, Salvetti, M, Ristori, G

“…Highlights • The various stages of the use of type I interferon in multiple sclerosis were reviewed. • We focused on the possible effects of the treatment on…”
Get full text

Abstract P5-12-02: PTEN alterations and tumor mutational burden (TMB) as potential predictors of resistance or response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC) by Barroso-Sousa, R, Tyekucheva, S, Pernas-Simon, S, Exman, P, Jain, E, Garrido-Castro, AC, Hughes, M, Bychkovsky, B, Di Lascio, S, Umeton, R, Files, J, Lindeman, NI, MacConaill, LE, Hodi, FS, Krop, IE, Dillon, D, Winer, EP, Wagle, N, Lin, NU, Mittendorf, EA, Tolaney, SM

“…Abstract Purpose: To date no biomarker has been identified that predicts response to ICI in mTNBC. This study aimed to explore if tumor genomic alterations…”
Get full text

Key Enzymes for the Optimization of CO2 Uptake and Nitrogen Consumption in the C3 Photosynthetic Carbon Metabolism by Papini, A., Nicosia, G., Stracquadanio, G., Liò, P., Umeton, R.

Get full text

Key Enzymes for the Optimization of CO 2 Uptake and Nitrogen Consumption in the C 3 Photosynthetic Carbon Metabolism by Papini, A., Nicosia, G., Stracquadanio, G., Liò, P., Umeton, R.

Get full text

Multiscale Mathematical Modeling to Support Drug Development by Nordsletten, David A., Yankama, Beracah, Umeton, Renato, Ayyadurai, V. A. Shiva, Dewey, C. Forbes

“…It is widely recognized that major improvements are required in the methods currently being used to develop new therapeutic drugs. The time from initial target…”
Get full text

Design of robust metabolic pathways by Umeton, Renato, Stracquadanio, Giovanni, Sorathiya, Anilkumar, Liò, Pietro, Papini, Alessio, Nicosia, Giuseppe

“…In this paper we investigate plant photosynthesis and microbial fuel cells. We report the following: 1) we introduce and validate a novel multi-objective…”
Get full text